profit from every $100 of sales.
$0$100
BlackRock Technology and Private Equity Term
$7.71-2.65% today
+16.1% in 1 year
1-year low $6.211-year high $9.49
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
You pay $103.59 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What BlackRock Technology and Private Equity Term sold, what it kept, and what it did with the cash.
Sales went from -$1.65 billion in 2022 to $11.5 million in 2025, with $8.69 million of profit last year.
SalesProfit
BlackRock Technology and Private Equity Term handed back 100% of the cash it generated last year.
Buybacks $724M
Free cash flow 2025$878M
Bought back its own shares$724M
Paid as dividends$153M
BlackRock Technology and Private Equity Term vs. similar companies
BlackRock Technology and Private Equity Term grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BlackRock Technology and Private Equity Term | 103.6× · Very expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads BlackRock Technology and Private Equity Term's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1,654 | 216 | 41 | 11 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| -1,656 | 212 | 36 | 9 | |
| -6.91 | 0.98 | 0.17 | – | |
| – | – | – | – | |
| – | – | – | – | |
| 100.2% | 98.1% | 87.7% | 75.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,057 | 2,067 | 1,809 | 939 |
| Cash | 0 | 0 | 0 | 0 |
| Total debt | – | – | – | – |
| Total liabilities | 30 | 41 | 24 | 24 |
| 2,026 | 2,026 | 1,785 | 915 | |
| 240 | 216 | 210 | – | |
| – | – | – | – | |
| -81.7% | 10.4% | 2.0% | 0.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 310 | 217 | 277 | 878 | |
| – | – | – | – | |
| 310 | 217 | 277 | 878 | |
| Dividends paid | 236 | 176 | 185 | 153 |
| 75 | 40 | 92 | 724 | |
| – | – | – | – |
Valuation
- 103.6×
- –
- –
- 1.9×
- 78.4×
- 1.0×
- –
- 97.6%
- 1.0%
- 9.3%
Profitability
- 100.0%
- 87.7%
- 75.7%
- 0.0%
- 3.8%
- -24.4%
- 2.6%
- 3.8%
- 3.8%
- –
Growth
- −76.9%
- –
- +216.7%
- –
- −4.6%
Financial health
- 0.0×
- 0.00
- 0.0%
- 2,313.2×
- 0.13
- 0.13
- 0.04
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 42%of 952
Top 1%of 883
Bottom 8%of 601
Bottom 1%of 888
Top 1%of 987
9.3%of the share price, paid each year
On $1,000 invested$93a year at today's yield, before tax
–per share
Raised2 yearsin a row, in our data
Paid per share, each year
$0.70 in 2021 → $0.90 in 2025
How safe it looks
1,765.9% of its profit
Room to growStretchedMore than it earns: 17.5%
News
Opposition to data centers will drive up inflation, says BlackRock’s Larry FinkMarketWatch · Oct 21, 2026BlackRock Is Building a Bitcoin ETF for Investors Who Can't Stomach the SwingsYahoo Finance · Oct 20, 2026Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and MoreYahoo Finance · Oct 20, 2026BlackRock’s Fink sees AI shortages, not a bubble, as the bigger threatSeeking Alpha · Oct 20, 2026What Does BlackRock (BLK) Joining A $500 Billion AI Funding Push Mean?Yahoo Finance · Oct 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
61Pass
Benjamin Graham
32No pass
Philip Fisher
67Pass
Peter Lynch
100Pass
Joel Greenblatt
8No pass
Charlie Munger
61Pass
Terry Smith
54No pass
Questions about BlackRock Technology and Private Equity Term
Is BlackRock Technology and Private Equity Term a good stock to buy?
A strong, very profitable business, priced as if everything goes right. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BlackRock Technology and Private Equity Term AI analysis
What does BlackRock Technology and Private Equity Term do?
BlackRock Innovation and Growth Trust (the Trust) is a newly-organized, non-diversified, closed-end management investment company with no operating history. It is in Biotechnology.
Does BlackRock Technology and Private Equity Term pay a dividend?
Yes. At today's price the dividend is 9.3% a year. In 2025 it paid out $153 million in dividends.
Is BlackRock Technology and Private Equity Term stock halal?
Yes. BlackRock Technology and Private Equity Term passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has BlackRock Technology and Private Equity Term stock done over the past year?
Up 16.1% over the past twelve months, to $7.71. It traded between $6.21 and $9.49 and is 18.8% below its high.
Who are BlackRock Technology and Private Equity Term's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BlackRock Technology and Private Equity Term's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.